NCT06573424

Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC

Efficacy AND Multiomic Molecular Characterization of Tirellizumab Combined With Anlotinib in in MSS/pMMR Metastatic Colorectal Cancer: Data From a Retrospective Multicenter Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 124 (actual)
• Sponsor: fan li · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer. To investigate the effective biomarker of anlotinib combined with tiralizumab

Detailed description

This was a multicenter retrospective cohort study to compare the efficacy of tyrosine kinase inhibitor（TKI） combined with immune checkpoint inhibitors(ICIs) versus tyrosine kinase inhibitor alone in the treatment of advanced MSS colorectal cancer. Patients with MSS CRC who have been confirmed by pathology and have relapsed or failed multiline therapy were included in the study. Patients who had received tirellizumab plus anlotinib were considered the combination group, and those treated with anlotinib were classified as the monotherapy group. The efficacy and safety of the two regimens were compared. At the same time, Whole-exome sequencing and transcriptome sequencing were performed on the patients in the response and non-response groups of the combination group to reveal the characteristics of their microenvironment and search for biomarkers related to response.

Conditions

• Colon Cancer
• Immunotherapy

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Tislelizumab+anlotinib	Patients who have been treated with anlotinib + tislelizumabline
DRUG	anlotinib	Patients who have been treated with anlotinib monotherapy

Timeline

• Start date: 2024-05-01
• Primary completion: 2024-07-01
• Completion: 2024-10-31
• First posted: 2024-08-27
• Last updated: 2025-05-01

Locations

1 site across 1 country: China